Cerus Corporation Submits Compassionate Use IDE Supplement For INTERCEPT Blood System Treatment Of Ebola Convalescent Plasma

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (NASDAQ:CERS) today announced submission of a clinical protocol to the U.S. Food and Drug Administration (FDA) to make the INTERCEPT Blood System for plasma available under a Compassionate Use Investigational Device Exemption (IDE) for treatment of convalescent plasma collected from Ebola disease survivors for passive immune therapy. A Compassionate Use IDE allows access to an unapproved product for U.S. patients with serious or life-threatening conditions for whom the treating physician believes the treatment may provide a benefit.

Help employers find you! Check out all the jobs and post your resume.

MORE ON THIS TOPIC